IDEAS home Printed from https://ideas.repec.org/a/epw/pharma/v2y2022i3id741.html

Formulation and Evaluation of Orodispersible Tablet of Sulindac

Author

Listed:
  • Bhavna B. Gaikwad

    (Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India)

  • Bhushan R. Rane

    (Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India)

  • Ashish S. Jain

    (Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India)

Abstract

Oral administration of dosage form is the most recommended mode of administration, because of its self-medication, accurate dose of the drug, and ease of administration. However, trouble swallowing in geriatric patients is one major negative of this route, which can mentally disrupt patients. The goal of this study was to use the direct compression method to make orodispersible tablets of sulindac utilizing various doses of super disintegrant agents such as Sodium starch glycolate Crospovidone and Croscarmellose sodium. Three distinct super disintegrants were used to create nine formulations with varying concentration levels. The preformulation, precompression, and post-compression properties of the powder combinations were assessed. In comparison to the other formulations, tablets from batch F3 containing crospovidone had superior organoleptic qualities, as well as outstanding drug release and in-vitro disintegration time. The super disntegrants addition technique was shown to be a viable method for manufacturing orodispersible tablets using the direct compression method.

Suggested Citation

Handle: RePEc:epw:pharma:v:2:y:2022:i:3:id:741
DOI: 10.24018/ejpharma.2022.2.3.41
as

Download full text from publisher

File URL: https://eu-opensci.org/index.php/pharma/article/view/741
File Function: Abstract page
Download Restriction: no

File URL: https://eu-opensci.org/index.php/pharma/article/download/741/307
File Function: Full text
Download Restriction: no

File URL: https://libkey.io/10.24018/ejpharma.2022.2.3.41?utm_source=ideas
LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
---><---

More about this item

Keywords

;
;
;
;
;
;

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:pharma:v:2:y:2022:i:3:id:741. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/pharma .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.